Compare Coursera Inc (COUR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coursera Inc vs Pfizer Inc — how do they compare? Coursera Inc trades at $5.65 (market cap $1.52B), while Pfizer Inc trades at $26.61 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 101.4× Coursera Inc's market cap, and Pfizer Inc pays a 6.36% dividend while Coursera Inc pays none. Which is the better fit depends on your goals.
| COUR | PFE | |
|---|---|---|
Market Cap | $1.52B | $154.18B |
Sector | Consumer Staples | Health |
52-Week High | $12.20 | $28.56 |
52-Week Low | $5.09 | $23.60 |
Enterprise Value | $778.04M | $205.67B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coursera (COUR) trades at $5.81, up 4.5% with bullish technical signals and strong analyst support. The company shows improving revenue growth ($757.5M in 2025, projected to $885M in 2026) but remains unprofitable with negative margins. Recent Q2 2026 earnings beat expectations with $0.17 EPS versus $0.10 estimate, while the company made a strategic $100M investment in AI education startup LearnVector.
The stock offers 32% upside to consensus price target of $7.70, supported by 53% buy ratings, but faces execution risks from persistent losses and competitive pressures in online education. Revenue growth trajectory and cost management will be critical for valuation improvement.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
